Krystal Biotech

Krystal Biotech, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, focused on developing genetic medicines for severe and rare diseases. The company specializes in redosable gene therapies, utilizing a proprietary technology platform that allows for repeated administration to effectively treat chronic genetic conditions. Krystal's core technology features a modified HSV-1 vector designed for safe and localized gene delivery. This innovative approach supports tailored treatment regimens, enhancing therapeutic outcomes. The company’s flagship product, VYJUVEK® (bercolagene telserpavec), is the first FDA-approved redosable gene therapy for dystrophic epidermolysis bullosa, addressing issues related to collagen production in skin cells. Krystal also has a pipeline of investigational therapies targeting various genetic disorders in dermatology, respiratory, and systemic diseases. With two in-house GMP facilities, Krystal ensures high-quality production of its therapies. The company emphasizes a patient-centric commercialization model, focusing on accessibility and engagement with medical professionals and rare disease patients. Krystal is publicly traded on NASDAQ under the ticker KRYS.